DVAX Dynavax Technologies Corp
Price (delayed)
$13.69
Market cap
$1.7B
P/E Ratio
65.19
Dividend/share
N/A
EPS
$0.21
Enterprise value
$1.85B
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of
Highlights
DVAX's EPS is up by 40% from the previous quarter
DVAX's price to earnings (P/E) is 35% lower than its last 4 quarters average of 99.7
DVAX's quick ratio is down by 24% YoY and by 19% QoQ
Dynavax Technologies's equity has decreased by 12% from the previous quarter and by 4.1% YoY
Key stats
What are the main financial stats of DVAX
Market
Valuations
Earnings
Shares outstanding
124.07M
Market cap
$1.7B
Enterprise value
$1.85B
Price to earnings (P/E)
65.19
Price to book (P/B)
3.02
Price to sales (P/S)
6.42
EV/EBIT
49.21
EV/EBITDA
40.54
EV/Sales
6.68
Revenue
$277.25M
Gross profit
$227.8M
Operating income
-$4.12M
Net income
$27.31M
EBIT
$37.65M
EBITDA
$45.7M
Free cash flow
$60.16M
Per share
Balance sheet
Liquidity
EPS
$0.21
EPS diluted
$0.2
Free cash flow per share
$0.46
Book value per share
$4.54
Revenue per share
$2.13
TBVPS
$7.57
Total assets
$986.26M
Total liabilities
$389.46M
Debt
$250.24M
Equity
$596.8M
Working capital
$770.31M
Debt to equity
0.42
Current ratio
10.8
Quick ratio
9.67
Net debt/EBITDA
3.38
Margins
Efficiency
Dividend
EBITDA margin
16.5%
Gross margin
82.2%
Net margin
9.9%
Operating margin
-1.5%
Return on assets
2.7%
Return on equity
4.3%
Return on invested capital
3.5%
Return on capital employed
4.1%
Return on sales
13.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DVAX stock price
How has the Dynavax Technologies stock price performed over time
Intraday
-0.36%
1 week
-4.53%
1 month
7.88%
1 year
12.49%
YTD
7.2%
QTD
7.2%
Financial performance
How have Dynavax Technologies's revenue and profit performed over time
Revenue
$277.25M
Gross profit
$227.8M
Operating income
-$4.12M
Net income
$27.31M
Gross margin
82.2%
Net margin
9.9%
The company's operating margin has surged by 91% YoY and by 64% QoQ
DVAX's operating income has soared by 89% year-on-year and by 62% since the previous quarter
The net income is up by 33% since the previous quarter
The company's gross profit rose by 25% YoY and by 5% QoQ
Growth
What is Dynavax Technologies's growth rate over time
Valuation
What is Dynavax Technologies stock price valuation
P/E
65.19
P/B
3.02
P/S
6.42
EV/EBIT
49.21
EV/EBITDA
40.54
EV/Sales
6.68
DVAX's EPS is up by 40% from the previous quarter
DVAX's price to earnings (P/E) is 35% lower than its last 4 quarters average of 99.7
DVAX's P/B is 61% below its 5-year quarterly average of 7.7 but 21% above its last 4 quarters average of 2.5
Dynavax Technologies's equity has decreased by 12% from the previous quarter and by 4.1% YoY
DVAX's revenue is up by 19% year-on-year and by 6% since the previous quarter
The P/S is 5% more than the last 4 quarters average of 6.1 but 4.2% less than the 5-year quarterly average of 6.7
Efficiency
How efficient is Dynavax Technologies business performance
Dynavax Technologies's ROA has increased by 35% from the previous quarter
The ROE has grown by 34% from the previous quarter
Dynavax Technologies's return on invested capital has increased by 21% QoQ
DVAX's ROS is up by 14% from the previous quarter
Dividends
What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DVAX.
Financial health
How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 153% higher than its total liabilities
DVAX's quick ratio is down by 24% YoY and by 19% QoQ
Dynavax Technologies's current ratio has decreased by 22% YoY and by 18% QoQ
Dynavax Technologies's debt is 58% less than its equity
The debt to equity has grown by 14% from the previous quarter and by 2.4% YoY
Dynavax Technologies's equity has decreased by 12% from the previous quarter and by 4.1% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.